Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

@article{RostamiHodjegan2007SimulationAP,
  title={Simulation and prediction of in vivo drug metabolism in human populations from in vitro data},
  author={Amin Rostami-Hodjegan and Geoffrey T Tucker},
  journal={Nature Reviews Drug Discovery},
  year={2007},
  volume={6},
  pages={140-148}
}
The perceived failure of new drug development has been blamed on deficiencies in in vivo studies of drug efficacy and safety. Prior simulation of the potential exposure of different individuals to a given dose might help to improve the design of such studies. This should also help researchers to focus on the characteristics of individuals who present with extreme reactions to therapy. An effort to build virtual populations using extensive demographic, physiological, genomic and in vitro… Expand

Topics from this paper

Translation of In Vitro Metabolic Data to Predict In Vivo Drug–Drug Interactions: IVIVE and Modeling and Simulations
TLDR
This chapter provides an overview of these translational aspects and describes the prerequisite data, models and tools which can be applied for the prediction of metabolic drug–drug interactions (M-DDI). Expand
An integrated modelling approach for in vitro to in vivo extrapolations
Predicting in vivo drug toxicity from in vitro testing requires modelling those processes that are not reproduced in vitro. The most obvious difference between the two settings is the lack ofExpand
Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development
TLDR
The variety of questions that can be addressed by prospective or retrospective application of modeling and simulation and the impact this can have on clinical drug development are highlighted. Expand
In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level.
TLDR
This current review describes approaches that can be used for cardiac safety assessment at the population level, by accounting for various sources of variability including kinetics of the compound of interest. Expand
In Vitro – In Vivo Extrapolation
TLDR
Physiologically based pharmacokinetic modeling is a key component in the in vitro to in vivo extrapolation of systemic toxicity, providing an effective framework to integrate and extrapolate in vitro results to in vivo and to determine the relevance of these data in the context of environmental exposures. Expand
Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation
TLDR
The concepts and application of the major physiologically based prediction tools to extrapolate clearance, tissue distribution, and rate and extent of absorption from minimal in vitro or animal in vivo input data are outlined. Expand
In Vivo-In Vitro-In Silico Pharmacokinetic Modelling in Drug Development
TLDR
The current status of in vitro-in vivo extrapolation of hepatic clearance or physiologically based pharmacokinetic modelling is surveyed and some examples are given, highlighting advantages and disadvantages in applying them at various phases of drug development. Expand
Utilizing in vitro transporter data in IVIVE-PBPK: an overview
TLDR
A snapshot of challenges or shortcomings of in vitro and in vivo techniques for understanding the contribution of drug transporters to a drug’s pharmacokinetics is provided. Expand
The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development
TLDR
The role of PBPK modeling in drug discovery and development is described, the assumptions involved in integrating protein abundance data are outlined, and the advances made and expected in determining abundance of relevant proteins through mass spectrometric techniques are described. Expand
PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models
To assist with interpretation of drug pharmacokinetics (PK) in animals and humans, AU: Your article has been copyedited to be consistent with the style and usage of the rest of the volume. TheExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 70 REFERENCES
Application of in silico approaches to predicting drug--drug interactions.
TLDR
The present paper briefly reviews the application of some computational tools applied to predicting drug--drug interactions (DDIs), and will provide the reader with an idea of their utility. Expand
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.
TLDR
The use of the total hepatic input concentration of inhibitor together with in vitro K(i) values was the most successful method for the categorization of putative CYP inhibitors and for identifying negative drug-drug interactions. Expand
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
TLDR
The Simcyp® Population-Based ADME Simulator was used to predict median drug clearances and their associated variance from in vitro data and regardless of whether microsomal binding was considered, the predicted fold variability fell within 2-fold of the observed variability. Expand
'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.
TLDR
In silico simulation of M-DDI has the potential to add significant value to this process of drug development and the FDA has recently emphasised the importance of such collaboration. Expand
An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.
TLDR
In vitro metabolic screening can be questioned as a compound selection tool without a proven in vitro-in vivo correlation, due to uncertainty in calculating in vivo kinetics from in vitro enzyme kinetic data. Expand
DRUG-DRUG INTERACTIONS : CYP 2 D 6 PARADIGM
The success of in vitro derived Ki values for predicting drug-drug interactions in vivo has been mixed. For example, the use of hepatic input concentration of inhibitor has resolved the negative andExpand
Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations
TLDR
In contrast to purely empirical approaches, the physiological approach to predicting clearance gives an opportunity to integrate some of these complexities and, therefore, should provide more confidence in the prediction of clearance in humans. Expand
Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling
TLDR
IVIVE is more reliable than AS in predicting human clearance values for drugs mainly metabolized by CYP450 enzymes, suggesting that the place of AS methods in pre-clinical drug development warrants further scrutiny. Expand
Metabolism: Scaling-up from In Vitro to Organ and Whole Body
TLDR
In vitro studies involving purified isoenzymes, subcellular fragments, slices, and isolated cells can, in many instances, provide invaluable mechanistic insight inasmuch as the system allows for easy control of experimental variables. Expand
Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences
TLDR
Only partial success in predicting ethnic differences in clearance indicates the need for larger and more reliable databases on relevant variables and in silico predictions might be used with more confidence to decrease theneed for repeating pharmacokinetic studies in different ethnic groups. Expand
...
1
2
3
4
5
...